Last updated on January 2020

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin


Brief description of study

Primary Objective:

To demonstrate the noninferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin

Secondary Objectives:

  • To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on glycemic control
  • To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on body weight
  • To evaluate the safety of once weekly injection of efpeglenatide and once weekly injection of dulaglutide

Detailed Study Description

Study duration per participant is approximately 65 weeks including an up to 3-week Screening Period, a 56-week Treatment Period and a 6-week safety Follow-up Period.

Clinical Study Identifier: NCT03684642

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.